Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 20;11:342. doi: 10.3389/fnins.2017.00342

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Mowat, Occelli, Bartoe, Gervais, Bruewer, Querubin, Dinculescu, Boye, Hauswirth and Petersen-Jones.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Fundus photography. Subretinal injections of vectors were performed at 29–44 days of age; a representative intraoperative color photograph and schematic of the subretinal injection technique are shown in (A). The subretinal bleb often flattened significantly immediately after injection (B), and was visibly resolved within 24 h in all eyes. One month following injection, mild arteriolar attenuation was present in control, uninjected eyes (C), and mild preservation of normal arteriolar diameter was present in the treated region of AAV-Pde6a injected eyes (D). By 2 months following injection untreated eyes and untreated regions of AAV-Pde6a treated eyes had significant arteriolar and mild venular attenuation (E), which contrasted with preserved arteriolar and venular vessel diameters in the treated area (F). Dashed line delineates the injected area.